Q3 Revenue Slips 1.6% as $139.5M Investment Write-Down Drives $73.9M Net Loss
INVA sits 19% above its 52-week low of $17.87.
Summary
Total revenue came in at $106.1M, down 1.6% from $107.8M a year ago, as flat GSK royalty revenue of $58.1M and softer ex-U.S. inventory timing offset the product story. The product story is the bright spot: U.S. net product sales jumped 45% to $43.3M, led by GIAPREZA at $23.1M and XACDURO at $16.1M, keeping IST on track for at least $150M in full-year U.S. product sales. Operating income rose 21.9% to $42.2M, so the core business is improving even with the top line flat. The reported net loss of $73.9M, or $1.03 per share, is almost entirely non-cash — a $139.5M unfavorable fair value swing driven by Armata Pharmaceuticals' stock decline, leaving strategic investments at $535.5M. Cash stands at $581.4M and the company bought back 1,226,948 shares for $26.3M in the quarter, with $42.3M remaining under the $125M program. NUZOLVENCE is now commercially available in the U.S., the first new product launch contribution to watch into 2027.
At the time of this announcement, INVA was trading at $21.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $17.87 to $25.15. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: BusinessWire.